Compare AbbVie Inc (ABBV) vs Honest Company Inc (HNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Honest Company Inc — how do they compare? AbbVie Inc trades at $248.8 (market cap $441.94B), while Honest Company Inc trades at $5.2 (market cap $558.95M). The key difference: AbbVie Inc is far larger — about 790.7× Honest Company Inc's market cap, and AbbVie Inc pays a 2.77% dividend while Honest Company Inc pays none. Which is the better fit depends on your goals.
| ABBV | HNST | |
|---|---|---|
Market Cap | $441.94B | $558.95M |
Sector | Health | Consumer Staples |
52-Week High | $263.58 | $5.46 |
52-Week Low | $197.38 | $2.10 |
Enterprise Value | $506.19B | $462.56M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
HNST trades at $5.23, down 4.21% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows mixed fundamentals with Q2 2026 EPS beating estimates at $0.04 versus $0.00926 expected, though revenue declined to $342M in 2026 with a net loss of $12M. Operating cash flow improved to $57M in 2026, and strategic exits are showing progress according to recent company updates.
The outlook remains cautious due to persistent net losses and margin pressure, offset by improving cash flow and recent earnings beats. Key risks include sustained profitability challenges and competitive pressures in personal care markets, while analyst sentiment is mixed with 30% buy ratings amid ongoing turnaround efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →
